## Göran Jönsson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11766048/publications.pdf

Version: 2024-02-01

73 papers

9,155 citations

35 h-index 70 g-index

74 all docs

74 docs citations

times ranked

74

17734 citing authors

#	Article	IF	Citations
1	Mutational Processes Molding the Genomes of 21 Breast Cancers. Cell, 2012, 149, 979-993.	13.5	1,673
2	The Life History of 21 Breast Cancers. Cell, 2012, 149, 994-1007.	13.5	1,249
3	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature, 2020, 577, 561-565.	13.7	1,209
4	Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nature Genetics, 2008, 40, 102-107.	9.4	316
5	Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nature Communications, 2017, 8, 1738.	5.8	310
6	Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Research, 2010, 12, R36.	2.2	251
7	Gene Expression Profiling–Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome. Clinical Cancer Research, 2010, 16, 3356-3367.	3.2	235
8	Deep sequencing of uveal melanoma identifies a recurrent mutation in <i>PLCB4</i> . Oncotarget, 2016, 7, 4624-4631.	0.8	235
9	Genome-wide association study identifies three new melanoma susceptibility loci. Nature Genetics, 2011, 43, 1108-1113.	9.4	230
10	Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation. Cancer Discovery, 2014, 4, 674-687.	7.7	226
11	WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. Molecular Cancer, 2014, 13, 88.	7.9	213
12	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications, 2019, 10, 3163.	5.8	205
13	High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes and Cancer, 2007, 46, 543-558.	1.5	176
14	MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nature Communications, 2015, 6, 8755.	5.8	175
15	Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Research, 2010, 12, R42.	2.2	167
16	Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget, 2015, 6, 12297-12309.	0.8	148
17	Distinct Genomic Profiles in Hereditary Breast Tumors Identified by Array-Based Comparative Genomic Hybridization. Cancer Research, 2005, 65, 7612-7621.	0.4	147
18	Identification of Subtypes in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome. Journal of Clinical Oncology, 2010, 28, 1813-1820.	0.8	145

#	Article	IF	CITATIONS
19	High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Research, 2010, 12, R25.	2.2	123
20	<i><scp>NF</scp>1</i> â€mutated melanoma tumors harbor distinct clinical and biological characteristics. Molecular Oncology, 2017, 11, 438-451.	2.1	112
21	Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma. Clinical Cancer Research, 2012, 18, 4026-4036.	3.2	96
22	Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome. Clinical Cancer Research, 2014, 20, 6127-6140.	3.2	91
23	Prognostic Impact of Array-based Genomic Profiles in Esophageal Squamous Cell Cancer. BMC Cancer, 2008, 8, 98.	1.1	77
24	High risk of tobacco-related cancers in <i>CDKN2A</i> mutation-positive melanoma families. Journal of Medical Genetics, 2014, 51, 545-552.	1.5	73
25	High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Research and Treatment, 2011, 129, 747-760.	1.1	70
26	The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma. Cell Reports, 2019, 27, 3573-3586.e7.	2.9	66
27	Mapping of a Novel Ocular and Cutaneous Malignant Melanoma Susceptibility Locus to Chromosome 9q21.32. Journal of the National Cancer Institute, 2005, 97, 1377-1382.	3.0	63
28	Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors. International Journal of Cancer, 2006, 119, 1052-1060.	2.3	59
29	Molecular and genetic diversity in the metastatic process of melanoma. Journal of Pathology, 2014, 233, 39-50.	2.1	58
30	Normalization of array-CGH data: influence of copy number imbalances. BMC Genomics, 2007, 8, 382.	1.2	57
31	Monitoring of Technical Variation in Quantitative High-Throughput Datasets. Cancer Informatics, 2013, 12, CIN.S12862.	0.9	47
32	Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. Journal of Investigative Dermatology, 2015, 135, 1820-1828.	0.3	46
33	Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours. Breast Cancer Research and Treatment, 2012, 133, 583-594.	1.1	44
34	The Retinoblastoma Gene Undergoes Rearrangements in <i>BRCA1</i> -Deficient Basal-like Breast Cancer. Cancer Research, 2012, 72, 4028-4036.	0.4	41
35	Relation between smoking history and gene expression profiles in lung adenocarcinomas. BMC Medical Genomics, 2012, 5, 22.	0.7	41
36	B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?. Clinical Cancer Research, 2022, 28, 1751-1758.	3.2	39

#	Article	IF	CITATIONS
37	The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response. Cancers, 2020, 12, 742.	1.7	38
38	A Preclinical Model of Malignant Peripheral Nerve Sheath Tumor-like Melanoma Is Characterized by Infiltrating Mast Cells. Cancer Research, 2016, 76, 251-263.	0.4	33
39	Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline <i>CDKN2A</i> mutations. Journal of Medical Genetics, 2020, 57, 316-321.	1.5	33
40	Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns. Melanoma Research, 2010, 20, 381-391.	0.6	30
41	DNA methylation subgroups in melanoma are associated with proliferative and immunological processes. BMC Medical Genomics, 2015, 8, 73.	0.7	29
42	Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma. Molecular Oncology, 2020, 14, 933-950.	2.1	29
43	Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs. BMC Clinical Pathology, 2008, 8, 6.	1.8	28
44	Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma. Clinical Cancer Research, 2019, 25, 7424-7435.	3.2	27
45	Correlation of histopathologic characteristics to protein expression and function in malignant melanoma. PLoS ONE, 2017, 12, e0176167.	1.1	27
46	Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer. Breast Cancer Research, 2011, 13, R129.	2.2	25
47	Vaccination against encapsulated bacteria in hereditary C2 deficiency results in antibody response and opsonization due to antibody-dependent complement activation. Clinical Immunology, 2012, 144, 214-227.	1.4	24
48	Gain of chromosomal region 20q and loss of 18 discriminates between Lynch syndrome and familial colorectal cancer. European Journal of Cancer, 2013, 49, 1226-1235.	1.3	23
49	Consensus of Melanoma Gene Expression Subtypes Converges on Biological Entities. Journal of Investigative Dermatology, 2016, 136, 2502-2505.	0.3	23
50	Molecular Characterization of Melanoma Cases in Denmark Suspected of Genetic Predisposition. PLoS ONE, 2015, 10, e0122662.	1.1	21
51	Comparative genomics reveals that loss of lunatic fringe ( <i>LFNG</i> ) promotes melanoma metastasis. Molecular Oncology, 2018, 12, 239-255.	2.1	20
52	Loss of CITED1, an MITF regulator, drives a phenotype switch <i>in vitro</i> and can predict clinical outcome in primary melanoma tumours. PeerJ, 2015, 3, e788.	0.9	20
53	<scp><i>CDKN2a</i></scp> mutationâ€negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies. International Journal of Cancer, 2015, 137, 2220-2226.	2.3	19
54	A Protein Deep Sequencing Evaluation of Metastatic Melanoma Tissues. PLoS ONE, 2015, 10, e0123661.	1.1	19

#	Article	IF	Citations
55	Genome-wide search for breast cancer linkage in large Icelandic non-BRCA1/2 families. Breast Cancer Research, 2010, 12, R50.	2.2	18
56	Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. Clinical and Experimental Metastasis, 2013, 30, 867-876.	1.7	16
57	Establishing a Southern Swedish Malignant Melanoma OMICS and biobank clinical capability. Clinical and Translational Medicine, 2013, 2, 7.	1.7	15
58	Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients. Arthritis Research and Therapy, 2020, 22, 36.	1.6	15
59	Different cell cycle kinetic effects of N 1,N 11-diethylnorspermine-induced polyamine depletion in four human breast cancer cell lines. Anti-Cancer Drugs, 2008, 19, 359-368.	0.7	14
60	The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients. Arthritis Research and Therapy, 2015, 17, 124.	1.6	14
61	Tumor Genome Wide DNA Alterations Assessed by Array CGH in Patients with Poor and Excellent Survival following Operation for Colorectal Cancer. Cancer Informatics, 2007, 3, 117693510700300.	0.9	13
62	Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma. Melanoma Research, 2019, 29, 483-490.	0.6	13
63	Molecular mechanisms underlying N 1, N 11-diethylnorspermine-induced apoptosis in a human breast cancer cell line. Anti-Cancer Drugs, 2008, 19, 871-883.	0.7	9
64	Feasibility Study on Measuring Selected Proteins in Malignant Melanoma Tissue by SRM Quantification. Journal of Proteome Research, 2014, 13, 1315-1326.	1.8	9
65	Immune responses following meningococcal serogroups A, C, Y and W polysaccharide vaccination in C2-deficient persons: Evidence for increased levels of serum bactericidal antibodies. Vaccine, 2015, 33, 1839-1845.	1.7	9
66	Primary Melanoma Tumors from CDKN2A Mutation Carriers Do Not Belong to a Distinct Molecular Subclass. Journal of Investigative Dermatology, 2014, 134, 3000-3003.	0.3	8
67	Effect of polyamine deficiency on proteins involved in Okazaki fragment maturation. Cell Biology International, 2008, 32, 1467-1477.	1.4	7
68	Tumor genome wide DNA alterations assessed by array CGH in patients with poor and excellent survival following operation for colorectal cancer. Cancer Informatics, 2007, 3, 341-55.	0.9	7
69	Nonfamilial Breast Cancer Subtypes. Methods in Molecular Biology, 2013, 973, 279-295.	0.4	5
70	Advances in molecular profiling of malignant melanoma: ready for clinical practice?. Melanoma Management, 2014, 1, 3-6.	0.1	0
71	The Genetic Evolution of Melanoma. , 2018, , 105-114.		0
72	Melanoma Genetics and Genomics. , 2011, , 57-77.		0

# ARTICLE IF CITATIONS

73 Melanoma Genetics and Genomics., 2017,, 63-93. 0